Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017
For Celldex Therapeutics (NASDAQ: CLDX), 2016 was a horrible year. The biotech stock dropped 77% after experimental vaccine Rintega flopped in a late-stage clinical study. Celldex entered 2017 with investors having both hope and fear. Unfortunately, fear outweighed hope for much of the year.
Celldex stock is down more than 15% so far this year despite several nice rallies during the last 11 months. Here's where things went wrong for the biotech in 2017.
Image source: Getty Images.
Source: Fool.com
Celldex Therapeutics Aktie
32,60 €
-4,12 %
Eine Tendenz zu Buy-Einschätzungen bei Celldex Therapeutics, überwiegend gegenüber Sell-Einschätzungen.
Das von der Community festgelegte Kursziel für Celldex Therapeutics von 56 € impliziert eine deutliche Steigerung gegenüber dem aktuellen Kurs von 32.6 €.
